簡(jiǎn)介:3-去氮腺嘌呤A,3-Deazaneplanocin A hydrochloride是一種有效的組蛋白甲基轉(zhuǎn)移酶 (EZH2) 抑制劑。
3-去氮腺嘌呤A物理化學(xué)性質(zhì):
熔點(diǎn) |
168-169℃ |
分子式 |
C12H15ClN4O3 |
分子量 |
298.725 |
精確質(zhì)量 |
298.083282 |
PSA |
117.42 |
LogP |
0.5919 |
外觀性狀 |
white to beige |
儲(chǔ)存條件 |
﹣20°C |
水溶解性 |
H2O: ≥5mg/mL |
3-去氮腺嘌呤A詳細(xì)介紹:
中文名稱: |
3-去氮腺嘌呤A |
中文別名: |
3-去氮腺嘌呤A;(1S,2R,5R)-5-(4-氨基-1H-咪唑并[4,5-c]吡啶-1-基)-3-(羥基甲基)-3-環(huán)戊烯-1,2-二醇鹽酸鹽 |
英文名稱: |
3-Deazaneplanocin A hydrochloride |
英文別名: |
3-Cyclopentene-1,2-diol, 5-(4-amino-1H-imidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)-, hydrochloride (1:1), (1S,2R,5R)-;3-Deazaneplanocin A Hydrochloride;3-Deazaneplanocin A;3-deazaneplanocin A (DZNeP) HCl;3-Deazaneplanocin A (hydrochloride);3-DEAZANEPLANOCIN HCL;3-Deazaneplanocin hydrochloride;CS-0870;HY-12186;NSC 617989 hydrochloride;SureCN4304150;(-)-1-[(1R,4R,5S)-3-(Hydroxymethyl)-4,5-dihydroxy-2-cyclopenten-1-yl]4-aminoimidazo[4,5-c]pyridine hydrochloride;DZNep hydrochloride;1H-Imidazo[4,5-c]pyridine, 3-cyclopentene-1,2-diol deriv.;NSC 617989 HCl;3-deazaneplanocin A HCl;Histone Methyltransferase EZH2 Inhibitor, DZNep;DZNep;3-Deazaneplanocin A (DZNep) hydrochloride;3-Deazaneplanocin, HCl salt;C12H14N4O3.ClH;2161AH;s7120;A13947;(1S,2R,5R)-5-(4-Amino-1H-imidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-e |
CAS號(hào): |
120964-45-6 |
分子式: |
C12H15CLN4O3 |
分子量: |
298.73 |
詳細(xì)描述: |
博飛美科提供120964-45-6,3-去氮腺嘌呤A,3-Deazaneplanocin A (DZNep) hydrochloride,Perfemiker,上?,F(xiàn)貨。 Perfemiker,致力于提供高品質(zhì)、高性價(jià)比小分子化合物的產(chǎn)品。 Perfemiker小分子化合物大量庫(kù)存,提供超過(guò)2萬(wàn)種的抑制劑、激動(dòng)劑、拮抗劑等產(chǎn)品,是藥物及疾病研究的重要原料供應(yīng)商。 SAHH和EZH2抑制劑,3-Deazaneplanocin A hydrochloride 是一種有效的組蛋白甲基轉(zhuǎn)移酶 (EZH2) 抑制劑。 查詢關(guān)鍵詞:“120964-45-6,3-去氮腺嘌呤A,3-Deazaneplanocin A (DZNep) hydrochloride,Perfemiker,上?,F(xiàn)貨”。 |
3-去氮腺嘌呤A參考文獻(xiàn):
[1]. Fiskus W, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood, 2009, 114(13), 2733-2743.
[2]. Avan A, et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther. 2012 Aug;11(8):1735-46.
[3]. Kikuchi J, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012 Nov;78(2):138-43.
[4]. Sun F, et al. Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus?. Eur J Pharm Sci. 2015 Sep 18;77:290-302.